Calcium chloride linked camel milk derived casein nanoparticles for the delivery of sorafenib in hepatocarcinoma cells


1Department of Biological Sciences, Birla Institute of Technology and Science, Pilani Campus, Pilani (BITS-PILANI), 333031, India
2Department of Pharmacy, Birla Institute of Technology and Science, Pilani Campus, Pilani (BITS-PILANI), 333031, India
3R&D Healthcare Division Emami, Ltd., Kolkata, 700056, India
*Address correspondence to: Sunil Kumar Dubey, sunilbit2014@gmail.com; Uma S. Dubey, uma@pilani.bits-pilani.ac.in
Received: 24 January 2021; Accepted: 29 March 2021

Abstract: Sorafenib, a multikinase inhibitor used for the treatment of hepatocellular carcinoma, is limited by its low oral bioavailability. To overcome this drawback, we have developed novel camel milk casein-derived nanoparticles as a drug delivery system. Camel milk casein is not only biocompatible on oral administration but is actually a dietary protein of pharmaceutical relevance. Casein is used because of its amphiphilic nature, self-assembling property, ability to show sustained release, and capability of encapsulating both hydrophilic and hydrophobic drugs. In this study, camel milk casein nanoparticles loaded with sorafenib were developed and characterized. Characterization of casein nanoparticles was done by dynamic light scattering (DLS), zeta potential analysis, scanning light microscopy (SEM), and FTIR. The drug content in nanoparticle and drug-protein binding studies were conducted by UV spectroscopy. The cytotoxicity and cellular uptake efficiency studies were performed in HepG2 cell lines. It was observed that the cytotoxic effect of sorafenib loaded camel milk casein nanoparticles was more than free sorafenib in HepG2 cells. This work suggests camel milk casein as a suitable drug delivery molecule for sorafenib. In the future, it may also be used in enhancing the efficacy and specific distribution of other water-insoluble anticancer drugs.

Keywords: Camel milk derived casein nanoparticles; Sorafenib; UV spectroscopy; FTIR; HepG2 cells; Apoptosis


Nanotechnology has a very high potential in the diagnosis, treatment, and management of cancer (Gmeiner and Ghosh, 2015; Din et al., 2017). The characteristics properties of nanoparticles (NPs) like small size, customized surface, improved solubility, multi-functionality, and administration through different routes are of utmost importance (Krishna et al., 2019). These features overcome the disadvantages of using conventional chemotherapeutic agents (Singh and Lillard, 2009; Patra et al., 2018; Hejmady et al., 2020). Different nanocarriers such as liposomes, micelles, polymeric nanomaterials, mesoporous silica, metallic nanoparticles have been used in drug delivery for improving an array of biomedical applications (Krishna et al., 2020). Among various kinds of protein NPs, milk whey proteins, alpha-lactalbumin, β-lactoglobulin, caseins, etc., have been investigated for the delivery of drugs, nutraceuticals, and bioactive peptides. These GRAS natural derivatives have characteristics like biocompatibility, amphiphilicity, wide availability, lack of toxicity, non-antigenicity, and low cost, making them suitable for drug delivery, safety, and improved therapeutic potential of anticancer drugs (Lohcharoenkal et al., 2014).

Casein nanoparticles have a high drug loading capacity and are able to deliver both hydrophilic and hydrophobic drug molecules. The pH-dependent behavior of casein micelles makes it beneficial for the controlled release of substances administered orally. Furthermore, the unfolded structure of caseins makes them easily accessible for proteolysis, ensuring good release by proteolytic enzymes in the gastrointestinal tract. Additionally, caseins can penetrate the cell membrane in an energy-independent fashion, which can enhance cellular uptake on oral administration. Physiological degradation products of casein produce immunomodulatory peptides, antioxidants, and ACE inhibitors (which optimize blood pressure regulation). All of these features make casein a promising candidate for encapsulation matrix for anticancer drugs (Głąb and Boratyński, 2017; Sahu et al., 2008).

Camel milk has been traditionally consumed worldwide for its nutritional benefits and medicinal properties. It also has therapeutic and prophylactic benefits against cancer (Dubey et al., 2016; Al haj and Al Kanhal, 2010). Camel milk proteins have more thermostability and pH hydrolysis resistance (Atri et al., 2011). Camel milk casein is present in the micellar form, is easily biodegradable, has an amphiphilic character, is an antioxidant, and has a molecular chaperone-like activity (Kumar et al., 2016). Earlier, also camel casein has been used as an effective nano vehicle for curcumin, and its application has been suggested in functional health food formulations (Esmaili et al., 2011). Camel milk casein has the potential to bind with both polar and non-polar compounds and serve as a suitable nanocarrier for other physiological compounds, including drugs. Therefore, in our study, we have synthesized camel milk casein nanoparticles and used them as a carrier for encapsulating the drug sorafenib, which is an FDA-approved drug against human hepatocellular carcinoma (HCC). HCC is the most common type of primary liver cancer and the most common cause of death in people with cirrhosis (Balogh et al., 2016).

Kinases play a very important role in tumor cell signaling, angiogenesis, and apoptosis (Krishna et al., 2021). Sorafenib is a very promising anticancer drug with the properties of a multikinase inhibitor. It acts against several solid tumors by preventing cell proliferation, tumor growth, and angiogenesis (Jindal et al., 2019). However, sorafenib is a small-molecule drug, having poor aqueous solubility leading to low bioavailability. As it is a small-molecule drug, it may distribute throughout the whole body and be rapidly metabolized in the body leading to adverse effects (Babos et al., 2018). Camel milk is known to reduce drug-induced hepatic and renal toxicity, whereas casein-derived peptides are important pharmaceutically active molecules in addition to being immunomodulatory molecules (Głąb and Boratyński, 2017; Kumar et al., 2016). Therefore, in this study, we have explored the use of casein-derived nanoparticles from camel milk for the encapsulation of sorafenib. For this, we have initially developed and characterized camel casein nanoparticles. Later we studied the cellular uptake and cytotoxicity of sorafenib loaded casein nanoparticles in the HepG2 cell line.

Materials and Methods

Chemicals and reagents

SDS-PAGE molecular weight marker, MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium Bromide, DAPI (4’,6-diamidino-2-phenylindole) were purchased from Sigma (Bangalore, India), 2-Benzothiazolyl)-7-(diethylamino) coumarin (C6) was purchased from TCI Chemicals (India) Pvt. Ltd. All organic solvents were of HPLC grade.

Camel milk sample collection

Camel milk samples were collected from ‘Sarika Raika Milk Bhandar’, Jaipur, India. The sample was collected under aseptic conditions, stored at −20°C in a sterile container until further use.

Isolation and purification of casein protein from camel milk

Isolation of casein from camel (Camelus dromedarius) milk as was done according to the process described earlier (Salami et al., 2011; Kumar et al., 2016) with slight modification. Briefly, fat was removed from the milk by centrifugation at 8000 rpm for 30 min at 4°C. The supernatant containing skimmed milk was collected for further use. Whey and casein were separated by acid precipitation with 1 N HCl at pH 4.6 and centrifugation at 12000 rpm for 30 min at 4°C. The precipitated casein was washed thrice with distilled water. The precipitated casein pellet was kept at −20°C until further use and solubilized according to a reported method (Madadlou et al., 2009) briefly described as follows. Casein solution (5%) was prepared by adding 10 g casein protein to 200 mL of deionized water (pH 7.0), stirring at 1000 rpm for 60 min at room temperature, sodium azide (0.03%) was added to prevent any microbial contamination. The solution was stored at 4°C for 10–12 h to allow complete hydration. The pH of the solution, which was originally 6.48, was then adjusted to 7, 9, or 12, separately, by slow addition of 1 N sodium hydroxide solution with constant stirring.

Polyacrylamide gel electrophoresis

Skimmed milk and isolated camel milk casein protein were analyzed by SDS-PAGE on 12% gel under reducing condition by using a Bio-Rad mini gel electrophoresis unit run at 80 V. Before the electrophoresis, skimmed milk and casein protein samples were diluted to 2 μg/μL with the sample buffer. Sample denaturation was done for 5 min at 100°C, and protein samples were loaded to each well. Proteins in gel were stained by Coomassie Brilliant Blue R-250, and the gel image was viewed by the use of a gel documentation system (BioRad). Separated proteins were validated for identification using the molecular weight marker.

UV visible spectroscopy

Quantitative analysis of sorafenib and casein was performed by UV spectroscopy. Stock solutions of casein and sorafenib drug were prepared in MQ water and methanol, respectively. The UV absorption spectra were recorded on a UV-2700 spectrophotometer (Shimadzu Co., Kyoto, Japan) over a wavelength range of 200–300 nm, and λmax of these compounds was estimated from the calibration curve. The binding of sorafenib drug with casein micelles was analyzed by UV spectrophotometry.

Synthesis of camel milk casein nanoparticle

Casein nanoparticles were prepared according to an earlier reported method with some modifications (Gandhi and Roy, 2018). Five percent casein solution was mixed with the drug sorafenib at a concentration of 200 µg/mL and was stirred at 900 rpm at room temperature for 1 h. This was followed by the addition of 50 μL (10 mM) CaCl2 until the solution became turbid. This same has been explained pictorially in Fig. 1.


Figure 1: Pictorial representation of the synthesis of casein nanoparticles. (A) 5% casein solution with sorafenib drug. (B) Turbid mildly casein solution upon addition of calcium chloride (CaCl2). (C) Casein nanoparticle.

Characterization of camel milk casein nanoparticle

FTIR study

The physical compatibility between casein nanoparticles and sorafenib was investigated by FTIR spectroscopy. Briefly, the spectra of casein, sorafenib, their mixture (1:1), and sorafenib loaded casein nanoparticles were recorded using a Fourier Transformed-IR system (Alpha Bruker’s) equipped with a germanium attenuated total reflection (ATR) system. Lyophilized Solid samples of each were placed directly in the FT-IR sample holder in direct contact with the ATR crystal. IR spectra were obtained in the spectral region 4,000 cm−1 to 500 cm−1, in transmittance mode.

Physical property analysis and scanning electron microscopy of camel milk casein nanoparticles

The prepared casein nanoparticles were characterized for the size, polydispersity index (PDI), and zeta potential using a Zetasizer, Nano series (Nano-ZS, Malvern, UK). The casein nanoparticle diameter and surface charge/ZP were measured in water pH (6.2–7.4) at 25°C with a scattering angle of 90°C. Morphology was examined by scanning electron microscopy (SEM) at a voltage of 20 kV after coating with gold under vacuum. Drops of Nanoparticles samples were put on slides and were dried under nitrogen gas. Then these slides were placed on aluminum stubs fixed by double-sided tape and placed in the vacuum chamber of SEM (Thermo ScientificTM Apreo scanning electron microscope). Slides were seen from 30,000 × to 10,000 × magnifications.

Drug encapsulation efficiency

To quantify the drug content, 1 mL aliquot of the nanoparticle solution containing the drug was centrifuged at 10,000 rpm for 20 min at 4°C. Now the pellet was dissolved in methanol to precipitate the protein. Subsequently, it was vortexed for 1 h, followed by centrifugation at 6000 rpm for 10 min. The drug concentration in the pellet was determined using a UV spectrophotometer. Results have been presented as means ± SE of three independent experiments, each performed in duplicate. The encapsulation efficiency (E.E.) was calculated by using the following formula:

E.E. (%) = (mass of a drug in nanoparticles/mass of drug used in formulation) × 100.

Cell culture associated studies

Culture of cells

HepG2 cells procured from NCCS, Pune, India, were cultured at 37°C, 5% CO2, in minimum essential medium (Invitrogen) supplemented with 10% fetal bovine serum (Invitrogen) and 1% antibiotics solution–Penicillin (100 U mL−1) and streptomycin (100 μg mL−1; Invitrogen). Trypsin–EDTA solution (0.05%) was used for the detachment of cells. The cells were grown to 70% confluence in tissue culture flasks (Tarson), detached using Trypsin EDTA solution, rinsed in phosphate buffer saline, and finally transferred in complete fresh medium. Subsequently, they were analyzed for cellular uptake, viability, and morphological changes.

Cellular internalization study

Coumarin-6 (green-fluorescent dye) entrapped casein nanoparticles were prepared in the same way as described above in synthesis part. HepG2 cells were seeded on coverslips in six-well plates and treated with the 3 µg/mL of coumarin-6 entrapped casein nanoparticles at 37°C for 4 and 6 h, respectively. The cells were then washed twice with PBS to remove nanoparticles not taken up by the cells and fixed with methanol for 10 min. Subsequently, they were stained with DAPI (2 µg/mL) for 3–5 min and washed twice with PBS. Cells were mounted using glycerol and examined under a fluorescence microscope (Zeiss Axio Scope A1) using the filters for DAPI and FITC. The merged image was also obtained for better visualization.

Cytotoxicity assay

MTT (3-(4, 5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium Bromide) assay was used to determine the cytotoxicity of the drug, sorafenib, and its loaded casein nanoparticles. Briefly, HepG2 cells were seeded at a density of 8000 cells/well in a 96-well plate. After reaching the 70% confluence, cells were treated with different concentrations of the drug sorafenib and its loaded casein nanoparticles for 24 h. MTT was added to cells and incubated for 4 h at 37°C. Subsequently, the media was discarded and 150 μL of DMSO was added to each well. The color intensity was measured at 570 nm wavelength, using a microplate reader (Multiskan™ Thermo Scientific™). Each determination was carried out in triplicate and at least two independent experiments were carried out. Cell viability was calculated as using the following formula:

% Cell viability = OD of treated cells/OD of control (without treatment) × 100

DAPI staining

HepG2 cells were implanted on a coverslip in a 6-well plate and incubated with only sorafenib and casein encapsulated sorafenib, respectively, at 10 µM and 20 µM concentration for 24 h. Cells were then washed twice with PBS, fixed with ice-cold methanol, and again washed twice with PBS. Next, cells were stained with DAPI (2 μg/mL) and incubated for 10 min at room temperature in the dark. The cells were finally washed with PBS two times and visualized under a fluorescence microscope (ZEISS Axio Scope A1 microscope). The Apoptotic bodies were observed.

Statistical Analysis

Graphs and statistical analysis of data was performed by using GraphPad prism5 software. The data are given as the mean values ± SEM. Comparisons among inter and intra groups were analyzed using one-way and two-way ANOVA followed by the Bonferroni post test. P < 0.05 was considered to indicate a statistically significant difference. All experiments were repeated at least three times performed in triplicates.

Result and Discussion

Solubility and SDS PAGE analysis of camel milk casein protein

Camel milk casein was obtained at its isoelectric pH, i.e., 4.6 at room temperature. It is a hydrophobic protein, insoluble in water. At high pH (7, 9 and 12), casein will have a net negative charge (due to ionization of its acidic side chains); therefore, it was soluble after the addition of 1 N NaOH (sodium hydroxide) at all the three pH values, as shown in Fig. 2A. Camel milk casein is a major dietary phosphoprotein, which is of 4 types, namely, αs1 casein, αs2 casein, β casein, and k casein. The electrophoretic migration of camel milk casein has been depicted in Fig. 2B at the three different pH studied. The molecular weight of α-caseins, β-casein, and k-casein was observed to be about 28 kDa, 26 kDa, and 22 kDa, respectively, at each pH as expected and reported earlier (Yelubaeva et al., 2017; Kappeler et al., 1999). It was also clearly seen that the bands which correspond to whey protein in camel skimmed milk are decreased or disappeared in casein protein, depicting the relative purity of the isolated casein protein.


Figure 2: (A) Solubilization of camel milk casein solution at pH 7, 9, and 12. (B) SDS-PAGE image of solubilized casein at pH 7, 9, and 12. The molecular weight marker has been loaded in the 1st lane, skimmed camel milk (SM) in the 2nd lane, and camel milk casein at pH 7, 9, and 12 have been loaded in lanes 3, 4, and 5, respectively.

UV-visible spectroscopic analysis

Spectrum analysisof the drug sorafenib, camel milk casein, and the drug mixed with casein (not as nanoparticle) was determined by UV spectroscopy, and the respective λmax was determined and shown in Fig. 3. Casein (1 µg/mL) exhibits maximum absorption at the wavelength of 275 nm, as shown in Fig. 3A. It can be explained by the presence of the aromatic side-chains of amino acids like tryptophan (Trp), tyrosine (Tyr), and phenylalanine (Phe) residues which absorb in this range of wavelength (Goldfarb et al., 1951; Antosiewicz and Shugar, 2016). Sorafenib showed maximum absorbance at 264 nm at all the concentrations studied, ranging from 1–6 µg/mL. This corresponds to earlier studies (Onur, 2018) and has been shown in Fig. 3B. To investigate the effect of sorafenib interaction with camel milk casein for any structural changes induced mixture, the UV spectrum of casein was plotted taking various concentrations of sorafenib (Fig. 3C). The maximum absorption peak of casein alone was at 275 nm, and it remained unchanged in the presence of sorafenib at the concentration range studied. With the increase in sorafenib concentration, the absorbance of casein gradually increased from 0.6 to 0.9 at the same λmax(275 nm). This suggests that the polarity of the microenvironment around Trp and Tyr residues of casein has been changed by the drug, but this does not cause its conformational change in casein (Li et al., 2011; Yue et al., 2012). The linear calibration curve obtained on measuring the absorbance of the sorafenib at various concentrations has been shown in Fig. 3D, which has good linearity with a correlation coefficient of R2=0.998.


Figure 3: UV-Visible spectrum. (A) UV spectra of camel casein protein. (B) UV spectra of sorafenib at various dilutions. (C) UV spectra of casein (1 µM) in the absence and presence of different concentrations of Sorafenib drug (1–6 μM). (D) Calibration curve of sorafenib drug.

Synthesis of camel casein nanoparticle

In this study, we have indigenously prepared novel camel milk casein nanoparticles and have explored their use as a carrier for the anticancer drug sorafenib. Casein self-assembles into spherical micelles at pH 7 when dissolved in water, and sorafenib gets encapsulated into the hydrophobic core of casein micelles (Corzo-Martínez et al., 2015). This is further stabilized by the addition of calcium chloride solution, which also maintains the micellar integrity (Sosa-Herrera et al., 2012). The solution formed was mildly turbid due to the presence of densely formed casein nanoparticles (Penalva et al., 2015). Pictorial depiction of synthesis of nanoparticle done by us has been described earlier in Fig. 1, and its features are described subsequently. No exogenous cross-linkers and toxic chemicals were used in the process of preparation.

Characterization of camel milk casein nanoparticle

FTIR spectra analysis

The chemical analysis of the drug casein, physical mixture of casein, and drug, as well as the drug-loaded casein nanoparticle, was subjected to analysis by FTIR spectroscopy, as shown in Fig. 4. The mixture was also used in order to investigate any possible chemical association, change in composition, or compatibility between the drug and its carrier. The initial peaks higher than 3608 cm−1 are due to the solvent system in all four panels. The uppermost panel represents the sorafenib peak. The peaks at 3062 cm−1 and 2928 cm−1 (due to the C-H stretching band of aromatic and aliphatic CH, respectively) are evident. The sorafenib peak at 1696.4 cm−1 is characteristic of the amide group (C=O). Absorption peaks of casein (2nd panel from top) are at 3273 cm−1 (amide band) and at 1639 cm−1, which is mainly associated with the C=O stretching vibration and depends on the backbone conformation and hydrogen bonding. Casein also exhibits another characteristic band at 1442 cm−1 which may be attributed to the carboxylate group (O-C-O). The major absorption peaks shown in casein and drug spectra were also found in their physical mixture spectrum (3rd panel from the top) and casein loaded nanoparticle (4th panel from the top). FTIR spectral analysis as conducted by us revealed that the specific functional groups of casein as a carrier and the drug sorafenib in the nanoparticles have almost identical chemical characteristics of the pure casein and drug bound together. This indicates that there was not any significant chemical bonding between the two molecules, i.e., sorafenib was well encapsulated within casein nanoparticles. This is in line with the spectrometric analysis done earlier in above Fig. 3.


Figure 4: FTIR spectra of (1) sorafenib drug, (2) casein at pH 7, (3) a physical mixture of casein and drug, and (4) casein-loaded drug nanoparticle (NP).

Physical and morphological studies of unloaded and drug loaded camel casein nanoparticles

The novel camel casein nanoparticles were analyzed to determine their particle size, distribution, and zeta potential using the Malvern zeta sizer, shown in Fig. 5 and Tab. 1. Camel milk casein nanoparticles were found to have an average hydrodynamic particle size of 192 ± 5.4 nm with a polydispersity index of 0.22, whereas sorafenib-loaded camel casein nanoparticles had a slightly greater size, i.e., 212 ± 6 nm, with a narrow polydispersity index of 0.23 (shown in Tab. 1). This indicates that the particles were uniform and monodispersed. The entrapment efficiency of drug-loaded nanoparticles was observed to be 51.5 ± 3.2%. Zeta potential is the measure of the surface charge of NPs and has an important effect on the stability of the colloidal system. The zeta potential of casein nanoparticles was found to be negatively charged (data are shown in Tab. 1) because of the ionized carboxylic groups of sodium caseinate at pH 7. The negative surface charge is also indicative of low toxicity as compared to the positively charged nanoparticle, which internalizes the cells by various mechanisms that need to be explored further (Tang et al., 2018).


Figure 5: Measurement of nanoparticles. (A) Size and (B) zeta potential of casein nanoparticles by dynamic light scattering (DLS).


The shape of camel casein nanoparticles was analyzed using scanning electron microscopy (SEM). A smooth surface and spherical shape of the nanoparticles were observed as has been shown in Fig. 6. The size of particles ranges between 160–220 nm, which is in agreement with the dynamic light scattering studies done earlier (Penalva et al., 2015).


Figure 6: Scanning electron microscopic image of camel casein nanoparticles.

Cellular internalization study

Coumarin-6 encapsulated casein nanoparticle was used to study cellular uptake as it serves as a suitable fluorescent probe. The resulting fluorescence images depict that coumarin-6 dye-loaded nanoparticles were effectively taken up by the cells (Fig. 7). Coumarin-6 dye-loaded nanoparticles showed a preferentially higher accumulation in the cytoplasm as compared to the nucleus of HepG2 cells (after 4 h and 6 h of incubation), as compared to the only dye-treated cells. It can also be seen that the fluorescent intensity of Coumarin-6 encapsulated casein nanoparticles also increased within 2 h (between 4 h and 6 h) of the time interval. This enhanced cellular internalization associated with the nanoparticles could translate to better therapeutic efficacy.


Figure 7: Internalization study of fluorescent dye (coumarin)-loaded casein nanoparticle by fluorescence microscopy on HepG2 cells. (A) Fluorescent images of HepG2 cells after 4 h incubation with coumarin-loaded casein nanoparticle. (B) HepG2 cells after 4 h incubation with free coumarin. (C) Fluorescent images of HepG2 cells after 6 h incubation with coumarin-loaded casein nanoparticle. (D) HepG2 cells after 6 h incubation with free coumarin.

Cellular toxicity study

Cytotoxicity of our novel drug-loaded casein nanoparticles was evaluated in the HepG2 cell line by the MTT assay after 24 h. Improved cytotoxic efficacy of sorafenib in HepG2 cell line in-vitro, was observed as compared to the untreated control, as has been shown in Fig. 8. According to the results, the IC50 concentrations were determined as ~15 μM for sorafenib and ~10 μM for sorafenib loaded casein NPs, respectively. Sorafenib-loaded casein NPs had a remarkable activity on HepG2 cells at 10 μM concentration (48.5% cell viability), whereas it has been observed that when treated with non-encapsulated sorafenib there was (58% cell viability) at the same concentration. This can be due to better internalization of drug-loaded nanoparticles into the cells as compared to the only drug. Further, it was observed that the cytotoxicity increased with increasing concentration of drug in a statistically significant manner.


Figure 8: Cell viability of HepG2 cells treated with Sorafenib loaded casein nanoparticle and free Sorafenib. The data are given as the mean values ± SEM. **P < 0.01, ***P < 0.001, ns = non-significant.

To gain further insight into the mechanism involved, the cells were stained with DAPI, a nuclear stain. Cell shrinkage, nuclear fragmentation, and margination of the nucleus were observed in cells after treatment with the drug-loaded casein nanoparticle as well as with only sorafenib, as can be observed in Fig. 9. In untreated control cells, the nucleus was seen as normal without any condensation of nuclear material.


Figure 9: Fluorescence images of DAPI stained HepG2 cells treated with drug-loaded casein nanoparticle and only drug sorafenib. Magnification 60×. (A) Control cells without any treatment. (B) Cells treated with sorafenib loaded casein np (conc. 10 µm). (C) Cells treated with sorafenib loaded casein np (conc. 20 µm). (D) Cells treated with sorafenib (conc. 10 µm). (E) Cells treated with sorafenib (conc. 20 µm)


In the present study, novel camel milk casein nanoparticles were developed by us and loaded with the drug sorafenib to overcome its poor solubility and bioavailability. We have successfully developed the camel milk casein nanoparticles with a particle size of around 200 nm with a uniform spherical shape and negative charge. This drug-loaded nanoparticle had higher intracellular uptake of sorafenib as compared to the uptake of the only drug. The drug-loaded nanoparticles were found more cytotoxic and induced apoptosis in the mammalian hepatocarcinoma cell line, HepG2. In the future, the focus on in vivo pharmacokinetic studies of this developed anticancer drug delivery system is of high relevance.

Acknowledgement: We thank our institute BITS Pilani for providing all the logistic and infrastructural support for conducting thiswork. We also thank Raika Milk Bhandhar for providing fresh camel milk samples.

Availability of Data and Materials: All data generated or analyzed during this study are included in this published article.

Author Contribution: The authors confirm contribution to the paper as follows: Study conception and design: Uma S. Dubey, Sunil K Dubey. data collection: Aastha Mittal and Neelam Mahala, analysis and interpretation of results: Aastha Mittal and Krishna.V; draft manuscript preparation: Aastha, Sunil K Dubey, Uma S. Dubey. All authors reviewed the results and approved the final version of the manuscript.

Ethics Approval: No specific approval was required for this study.

Funding Statement: The authors received no specific funding for this study.

Conflicts of Interest: The authors declare that they have no conflicts of interest.


  1. Al haj OA, Al Kanhal HA (2010). Compositional, technological and nutritional aspects of dromedary camel milk. International Dairy Journal 20: 811–821. DOI 10.1016/j.idairyj.2010.04.003. [CrossRef]
  2. Antosiewicz, JM., & Shugar, D. (2016). UV-Vis spectroscopy of tyrosine side-groups in studies of protein structure. Part 2: Selected applications. Biophysical Reviews, 8, 163-177. [Google Scholar] [CrossRef]
  3. Atri, MS., Saboury, AA., Moosavi-Movahedi, AA., Goliaei, B., & Sefidbakht, Y. (2011). Structure and stability analysis of cytotoxic complex of camel α-lactalbumin and unsaturated fatty acids produced at high temperature. Journal of Biomolecular Structure and Dynamics, 28, 919-928. [Google Scholar] [CrossRef]
  4. Babos, G., Biró, E., Meiczinger, M., & Feczkó, T. (2018). Dual drug delivery of sorafenib and doxorubicin from PLGA and PEG-PLGA polymeric nanoparticles. Polymers, 10, 1-12. [Google Scholar] [CrossRef]
  5. Balogh, J., Victor, III D., Asham, EH., Burroughs, SG., & Boktour, M. (2016). Hepatocellular carcinoma: A review. Journal of Hepatocellular Carcinoma, 3, 41-53. [Google Scholar] [CrossRef]
  6. Corzo-Martínez, M., Mohan, M., Dunlap, J., & Harte, F. (2015). Effect of ultra-high pressure homogenization on the interaction between bovine casein micelles and ritonavir. Pharmaceutical Research, 32, 1055-1071. [Google Scholar] [CrossRef]
  7. Din, FU., Aman, W., Ullah, I., Qureshi, OS., Mustapha, O., Shafique, S., & Zeb, A. (2017). effective use of nanocarriers as drug delivery systems for treatment of selected tumors. International Journal of Nanomedicine, 12, 7291-7309. [Google Scholar] [CrossRef]
  8. Dubey US, Lal M, Mittal A, Kapur S (2016). Therapeutic potential of camel milk. Emirates Journal of Food and Agriculture 28: 164–176. DOI 10.975/ejfa.2015-04-122. [CrossRef]
  9. Esmaili, M., Ghaffari, SM., Moosavi-Movahedi, Z., Atri, MS., & Sharifizadeh, A. (2011). Beta casein-micelle as a nano vehicle for solubility enhancement of curcumin; food industry application. LWT-Food Science and Technology, 44, 2166-2172. [Google Scholar] [CrossRef]
  10. Gandhi, S., & Roy, I. (2018). Doxorubicin-loaded casein nanoparticles for drug delivery: Preparation, characterization and evaluation. International Journal of Biological Macromolecules, 121, 6-12. [Google Scholar]
  11. Głąb, TK., & Boratyński, J. (2017). Potential of casein as a carrier for biologically active agents. Topics in Current Chemistry, 375, 1-20. [Google Scholar] [CrossRef]
  12. Gmeiner, WH., & Ghosh, S. (2015). Nanotechnology for cancer treatment. Nanotechnology Reviews, 3, 111-122. [Google Scholar] [CrossRef]
  13. Goldfarb AR, Saidel LJ, Moscovich E (1951). The ultraviolet absorption spectra of proteins. Journal of Biological Chemistry 193: 397–404.
  14. Hejmady, S., Pradhan, R., Alexander, A., Agrawal, M., & Singhvi, G. (2020). Recent advances in targeted nanomedicine as promising antitumor therapeutics. Drug Discovery Today, 25, 2227-2244. [Google Scholar] [CrossRef]
  15. Jindal, A., Thadi, A., & Shailubhai, K. (2019). Hepatocellular carcinoma: Etiology and current and future drugs. Journal of Clinical and Experimental Hepatology, 9, 221-232. [Google Scholar] [CrossRef]
  16. Kappeler, S., Farah, Z., & Puhan, Z. (1999). Sequence analysis of Camelus dromedarius milk caseins. InterJournal of Dairy Research, 9, 481-486. [Google Scholar] [CrossRef]
  17. Krishna, KV., Saha, RN., & Dubey, SK. (2020). Biophysical, biochemical, and behavioral implications of ApoE3 conjugated donepezil nanomedicine in a Aβ1-42 induced Alzheimer’s disease rat model. ACS Chemical Neuroscience, 11, 4139-4151. [Google Scholar] [CrossRef]
  18. Krishna, KV., Wadhwa, G., Alexander, A., Kanojia, N., & Saha, RN. (2019). Design and biological evaluation of lipoprotein-based donepezil nanocarrier for enhanced brain uptake through oral delivery. ACS Chemical Neuroscience, 10, 4124-4135. [Google Scholar] [CrossRef]
  19. Krishna, KV., Dubey, SK., Singhvi, G., Gupta, G., & Kesharwani, P. (2021). MAPK pathway: Potential role in glioblastoma multiformurgery. Interdisciplinary Neurosurgery: Advanced Techniques and Case Management, 23, 100901. [Google Scholar] [CrossRef]
  20. Kumar, D., Chatli, MK., Singh, R., Mehta, N., & Kumar, P. (2016). Enzymatic hydrolysis of camel milk casein and its antioxidant properties. Dairy Science and Technology, 96, 391-404. [Google Scholar] [CrossRef]
  21. Li, D., Zhu, M., Xu, C., & Ji, B. (2011). Characterization of the baicalein e- bovine serum albumin complex without or with Cu or Fe by spectroscopic approaches. European Journal of Medicinal Chemistry, 46, 588-599. [Google Scholar] [CrossRef]
  22. Lohcharoenkal, W., Wang, L., Chen, YC., & Rojanasakul, Y. (2014). Protein nanoparticles as drug delivery carriers for cancer therapy. BioMed Research International, 2014, 180549. [Google Scholar] [CrossRef]
  23. Madadlou, A., Mousavi, ME., Emam-Djomeh, Z., Sheehan, D., & Ehsani, M. (2009). Alkaline pH does not disrupt re-assembled casein micelles. Food Chemistry, 116, 929-932. [Google Scholar] [CrossRef]
  24. Onur, S. (2018). Rapid determination and validation of sorafenib via uv-visible method in pharmaceutical formulations. Balıkesir Sağlık Bilimleri Dergisi, 7, 87-92. [Google Scholar]
  25. Patra, JK., Das, G., Fraceto, LF., Vangelie, E., & Campos, R. (2018). Nano based drug delivery systems: Recent developments and future prospects. Journal of Nanobiotechnology, 16, 1-33. [Google Scholar] [CrossRef]
  26. Penalva, R., Esparza, I., Agüeros, M., Gonzalez-Navarro, CJ., Gonzalez-Ferrero, C., & Irache, JM. (2015). Casein nanoparticles as carriers for the oral delivery of folic acid. Food Hydrocolloids, 44, 399-406. [Google Scholar]
  27. Sahu, A., Kasoju, N., & Bora, U. (2008). Fluorescence study of the curcumin-casein micelle complexation and its application as a drug nanocarrier to cancer cells. Biomacromolecules, 9, 2905-2912. [Google Scholar]
  28. Salami, M., Moosavi-Movahedi, AA., Moosavi-Movahedi, F., Ehsani, MR., & Yousefi, R. (2011). Biological activity of camel milk casein following enzymatic digestion. Journal of Dairy Research, 78, 471-478. [Google Scholar] [CrossRef]
  29. Singh, R., & Lillard, JW. (2009). Nanoparticle-based targeted drug delivery. Experimental & Molecular Pathology, 86, 215-223. [Google Scholar] [CrossRef]
  30. Sosa-Herrera, MG., Lozano-Esquivel, IE., Ponce de León-Ramírez, YR., & Martínez-Padilla, LP. (2012). Effect of added calcium chloride on the physicochemical and rheological properties of aqueous mixtures of sodium caseinate/sodium alginate and respective oil-in-water emulsions. Food Hydrocolloids, 29, 175-184. [Google Scholar] [CrossRef]
  31. Tang, X., Chen, L., Li, A., Cai, S., & Zhang, Y. (2018). Anti-GPC3 antibody-modified sorafenib-loaded nanoparticles significantly inhibited HepG2 hepatocellular carcinoma. Drug Delivery, 25, 1484-1494. [Google Scholar] [CrossRef]
  32. Yelubaeva, MY., Buralkhiev, BA., Serikbayeva, AD., Narmuratova, MH., & Kenenbay, SY. (2017). Electrophoretic identification of casein in various types of milk. OnLine Journal of Biological Sciences, 17, 348-352. [Google Scholar]
  33. Yue, Q., Shen, T., Wang, C., Gao, C., & Liu, J. (2012). Study on the interaction of bovine serum albumin with ceftriaxone and the inhibition effect of zinc (II). International Journal of Spectroscopy, 2012, [Google Scholar] [CrossRef]
images This work is licensed under a Creative Commons Attribution 4.0 International License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.